Fabien Squara1, Mikael Bres2, Didier Scarlatti2, Pamela Moceri2, Emile Ferrari2. 1. Hôpital Pasteur, Service de Cardiologie, 30 avenue de la Voie Romaine, CS 51069 06001, Nice Cedex 1, France. fabiensquara@gmail.com. 2. Hôpital Pasteur, Service de Cardiologie, 30 avenue de la Voie Romaine, CS 51069 06001, Nice Cedex 1, France.
Abstract
BACKGROUND: Direct-current cardioversion (DCC) for atrial fibrillation carries a risk of stroke, probably associated with the temporary atrial stunning following cardioversion. The presence of a cardiac thrombus, usually localized in the left atrial appendage (LAA), is recognized as a clear contra-indication to the cardioversion. However, the presence of atrial sludge without LAA thrombus in trans-esophageal echocardiography (TEE) remains, for many cardiologists, a relative contra-indication to the cardioversion. The aim of this study was to evaluate the safety of DCC in patients presenting atrial sludge without LAA thrombus. METHODS: We prospectively included all consecutive patients demonstrating atrial sludge without LAA thrombus in TEE and undergoing DCC for persistent atrial fibrillation (AF). Safety of DCC was evaluated by the occurrence of clinical events at 1 month following cardioversion, i.e., up to the end of the atrial stunning period, as assessed by clinical examination and the standardized and validated Questionnaire for Verifying Stroke-Free Status (QVSFS). RESULTS: Over a period of 2 years, 21 patients presenting atrial sludge without LAA thrombus underwent DCC for AF. During the follow-up period of 1 month after DCC, no clinical embolic event, cardiac event, or unscheduled consultations/hospitalizations occurred. At 1 month, 67% of the patients remained in sinus rhythm. CONCLUSION: No clinical event occurred in patients demonstrating atrial sludge without thrombus and undergoing DCC for AF. These findings support current guidelines that only keep atrial thrombus as a contraindication to cardioversion, but warrant further investigation in large studies.
BACKGROUND: Direct-current cardioversion (DCC) for atrial fibrillation carries a risk of stroke, probably associated with the temporary atrial stunning following cardioversion. The presence of a cardiac thrombus, usually localized in the left atrial appendage (LAA), is recognized as a clear contra-indication to the cardioversion. However, the presence of atrial sludge without LAA thrombus in trans-esophageal echocardiography (TEE) remains, for many cardiologists, a relative contra-indication to the cardioversion. The aim of this study was to evaluate the safety of DCC in patients presenting atrial sludge without LAA thrombus. METHODS: We prospectively included all consecutive patients demonstrating atrial sludge without LAA thrombus in TEE and undergoing DCC for persistent atrial fibrillation (AF). Safety of DCC was evaluated by the occurrence of clinical events at 1 month following cardioversion, i.e., up to the end of the atrial stunning period, as assessed by clinical examination and the standardized and validated Questionnaire for Verifying Stroke-Free Status (QVSFS). RESULTS: Over a period of 2 years, 21 patients presenting atrial sludge without LAA thrombus underwent DCC for AF. During the follow-up period of 1 month after DCC, no clinical embolic event, cardiac event, or unscheduled consultations/hospitalizations occurred. At 1 month, 67% of the patients remained in sinus rhythm. CONCLUSION: No clinical event occurred in patients demonstrating atrial sludge without thrombus and undergoing DCC for AF. These findings support current guidelines that only keep atrial thrombus as a contraindication to cardioversion, but warrant further investigation in large studies.
Authors: Shadi Kalantarian; Hakan Ay; Randy L Gollub; Hang Lee; Kallirroi Retzepi; Moussa Mansour; Jeremy N Ruskin Journal: Ann Intern Med Date: 2014-11-04 Impact factor: 25.391
Authors: Alan S Go; Kristi Reynolds; Jingrong Yang; Nigel Gupta; Judith Lenane; Sue Hee Sung; Teresa N Harrison; Taylor I Liu; Matthew D Solomon Journal: JAMA Cardiol Date: 2018-07-01 Impact factor: 14.676
Authors: J F Meschia; T G Brott; F E Chukwudelunzu; J Hardy; R D Brown; I Meissner; L J Hall; E J Atkinson; P C O'Brien Journal: Stroke Date: 2000-05 Impact factor: 7.914
Authors: Andreas Goette; Jose L Merino; Michael D Ezekowitz; Dmitry Zamoryakhin; Michael Melino; James Jin; Michele F Mercuri; Michael A Grosso; Victor Fernandez; Naab Al-Saady; Natalya Pelekh; Bela Merkely; Sergey Zenin; Mykola Kushnir; Jindrich Spinar; Valeriy Batushkin; Joris R de Groot; Gregory Y H Lip Journal: Lancet Date: 2016-08-30 Impact factor: 79.321
Authors: I C Van Gelder; H J Crijns; P K Blanksma; M L Landsman; J L Posma; M P Van Den Berg; F L Meijler; K I Lie Journal: Am J Cardiol Date: 1993-09-01 Impact factor: 2.778